NuVinAir ReKlenz-X is safe for use in vehicles and can be used without damaging the interior. Photo courtesy of NuVinAir

With the onset of COVID-19, the public is more aware than ever of cross-contamination, which extends from your home to your business to your car, and beyond.

NuVinAir announced that its latest product, ReKlenz-X, has gotten approval from the Environmental Protection Agency (EPA) as an eco-friendly disinfectant. The company's Houston affiliate, Brian Ross, is selling the product.

ReKlenz-X kills 99.9 percent of germs, bacteria, and viruses in a vehicle's interior without compromising the integrity of the cabin. The product is on the EPA's "List N", which includes disinfectants for use to combat SARS-CoV-2, the virus that causes COVID-19."NuVinAir has proudly been at the forefront of helping ensure healthier commutes to drivers and passengers since launching in 2015. Adding this EPA-approved, oxygen-infused product that actually kills what's behind the coronavirus gives us an exciting extension to our 'Total Health' application," says Kyle Bailey, NuVinAir Global's CEO and founder.

"Our science-backed ReKlenz-X disinfectant cleans, protects, and disinfects safely and effectively — it's everything our automotive partners need in guaranteeing their customers' confidence in a safer, healthier vehicle," he continues.

To clean, the proprietary product uses an oxygen-enriched formula to quickly kills bacteria and viruses by destroying their cell walls through a process called oxidation. According to NuVinAir, ReKlenz-X contains no harsh chemicals, sticky residue, or dangerous volatile organic compounds. The result is a disinfected vehicle with no chemical smell.

ReKlenz-X is available in 32-ounce spray bottles through automotive dealerships, detail shops, rental-car companies, service centers, and vehicle fleets.

"Until now, any possible solution for killing the coronavirus was wrought with harmful chemicals, expensive equipment, and residue-leaving application devices that destroy the vehicle's interior," said Troy Blackwell, Chief Operating Officer for NuVinAir Global. "As a disinfectant and sanitizer, it can be applied to all interior vehicle surfaces using a microfiber towel. Paired with our premier detailing solution, ReNuSurface, as well as our patented Cyclone treatment, it takes deep cleaning to a whole new level for our automotive partners and their customers."

Dallas, Texas-based NuVinAir sells their products through a franchise system, similar to Line-X's business model.

------

This article originally ran on AutomotiveMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.